Articles

Here’s the breakdown on what’s really driving America’s runaway drug prices — and whether any of the current plans stand a chance to lower your pharmacy bill.

Contrary to what many economic models suggest, salaries aren’t constantly recalibrated based on skills or technology. They follow the economy and politics—and common sense: hire when needed, promote from within, and slow hiring when budgets tighten.

Two economists who have studied Intel warn that Trump’s move to take a stake in the company amounts to flashy optics, incoherent strategy, and a creeping politicization of economic policy.

Has the Inflation Reduction Act hindered pharmaceutical innovation? Evidence shows that the pharma industry can strategically manage disruptive change.

On the occasion of the 70th anniversary of Kalecki’s seminal lecture in Mexico on financing economic development, Jan Toporowski’s INET Working Paper considers the relevance of structuralism and Kalecki’s view of economic development for today.

The most likely outcome of the second Trump administration is a recession and an exacerbation of inequalities, and a further degradation of the living standards of working and middle-class Americans.

The money to support well-paid American jobs exists—it’s just being hoarded at the top. Economist William Lazonick argues that this is not just unfair; it’s a failure of the whole economic system.

New research reveals that rising insurance costs, reckless building, regulatory inaction, and big banks’ fossil fuel investments are driving a dangerous cycle that jeopardizes homeowners — and financial stability for everyone.

DeepSeek’s appearance is changing the AI landscape in more ways than we might think.

Dr. Victor Gurewich, a researcher and Harvard Medical School faculty member since 1965, discovered a breakthrough drug treatment for heart attacks and strokes with the potential to save millions, but institutional resistance and a U.S. healthcare system that puts profits over patients are keeping it out of reach.